Global Digital Biomarkers Market to reach USD 14,478.78 million by 2032 at a CAGR of 17.11% by 2032, Evaluates DelveInsight

According to DelveInsight's analysis, The Digital Biomarkers Market is primarily driven by the rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions, which require continuous monitoring and early detection. Increasing adoption of wearable devices and mobile health technologies enables real-time, remote collection of physiological and behavioral data, enhancing patient care and treatment outcomes. Additionally, growing investments in digital health, advances in artificial intelligence and machine learning for data analysis, and supportive regulatory initiatives for innovative healthcare solutions are further accelerating market growth. These factors collectively position digital biomarkers as a critical tool in modern healthcare.

DelveInsight's "Digital Biomarkers Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Digital Biomarkers companies actively working in the market.

To know more about why North America is leading the market growth in the Digital Biomarkers market, get a snapshot of the report Digital Biomarkers Market Trends
https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=promotion&utm_campaign=gpr

Digital Biomarkers Overview
Digital biomarkers are objective, quantifiable physiological and behavioral data collected through digital devices such as smartphones, wearable sensors, or implantables. They provide real-time insights into a patient's health status, disease progression, or response to treatment. Examples include heart rate variability, sleep patterns, activity levels, glucose monitoring, and gait analysis. Digital biomarkers are increasingly used in clinical trials, personalized medicine, and remote patient monitoring, enabling earlier detection of conditions, improved treatment decisions, and enhanced healthcare outcomes.

DelveInsight Analysis: The digital biomarkers market size was estimated at USD 4,104.21 million in 2024 and is expected to grow at a CAGR of 17.11% from 2025 to 2032, reaching USD 14,478.78 million by 2032.

Digital Biomarkers Market Insights
Geographically, North America is expected to command the largest share of the digital biomarkers market in 2024, fueled by the increasing prevalence of chronic conditions such as cardiovascular disease, neurological disorders, and diabetes, driven primarily by the aging population and the rising adoption of wearable devices.

To read more about the latest highlights related to Digital Biomarkers, get a snapshot of the key highlights entailed in the Digital Biomarkers Insights
https://www.delveinsight.com/report-store/digital-biomarkers-market?utm_source=openpr&utm_medium=promotion&utm_campaign=gpr

Recent Developments in the Digital Biomarkers Market Report
• In June 2025, Agenus and Noetik announced a collaboration to develop AI-enabled predictive biomarkers for BOT/BAL using foundation models of virtual cell biology. This partnership aims to advance precision immunotherapy by using AI-driven virtual cell models to identify patients most likely to benefit from BOT/BAL treatment.
• In March 2025, Lunit announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative AI applications in cancer research. The partnership focuses on developing AI-driven digital biomarkers for tumor microenvironment analysis and immune phenotyping, aiming to uncover insights from NCI data that could advance personalized cancer care.
• In March 2025, BostonGene announced a collaboration to evaluate biomarkers for colorectal cancer and multiple myeloma using AI-driven molecular profiling in clinical trials. This initiative aims to enhance cancer treatment strategies by leveraging advanced AI technologies to identify clinically relevant biomarkers.
• Thus, owing to such developments in the market, rapid growth will be observed in the Digital Biomarkers market during the forecast period

Key Players in the Digital Biomarkers Market
Some of the key market players operating in the Digital Biomarkers market include- BioSensics, AliveCor, Inc., Eyenuk, Inc., Quibim, Huma, Evidation Health, Inc., Oura Health Oy, Biobeat, Omada Health Inc., F. Hoffmann-La Roche Ltd., Koneksa Health, Altoida, Empatica Inc., VivoSense, IXICO plc, Proscia Inc., Agenus Inc., Lunit, BostonGene Corporation, PathAI, Inc., and others.

Which MedTech key players in the Digital Biomarkers market are set to emerge as the trendsetter explore @ Key Digital Biomarkers Companies
https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=promotion&utm_campaign=gpr

Analysis on the Digital Biomarkers Market Landscape
The growth of this category is further supported by continuous technological advancements, especially in wearable devices that facilitate real-world data collection. For instance, in 2025, Google obtained FDA clearance for its Loss of Pulse Detection feature on the Pixel Watch 3. This innovative functionality can detect a user's pulse loss and automatically contact emergency services if the user is unresponsive. By converting passive sensor data into clinically relevant digital biomarkers, such wearables highlight the expanding role of physiological monitoring in healthcare. Consequently, the development of advanced FDA-cleared wearable technologies, coupled with increasing demand for personalized, continuous monitoring, is driving the rapid growth of the physiological biomarkers segment.
The rising prevalence of chronic diseases, along with the advantages offered by digital physiological biomarkers, is expected to significantly contribute to category growth, boosting global market revenues and playing a crucial role in propelling the overall digital biomarkers market from 2025 to 2032.

Scope of the Digital Biomarkers Market Report
• Coverage: Global
• Study Period: 2022-2032
• Digital Biomarkers Market Segmentation By Product Type: Wearable Devices, Implantable Devices, and Application/Software
• Digital Biomarkers Market Segmentation By Biomarker Type: Physiological Biomarkers, Behavioral Biomarkers, and Biochemical Biomarkers
• Digital Biomarkers Market Segmentation By Indication: Neurological Disease, Cardiovascular Disease, Metabolic Disease, and Others
• Digital Biomarkers Market Segmentation By Application: Diagnostic Biomarker, Monitoring Biomarker, and Predictive Biomarker
• Digital Biomarkers Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Digital Biomarkers Companies: BioSensics, AliveCor, Inc., Eyenuk, Inc., Quibim, Huma, Evidation Health, Inc., Oura Health Oy, Biobeat, Omada Health Inc., F. Hoffmann-La Roche Ltd., Koneksa Health, Altoida, Empatica Inc., VivoSense, IXICO plc, Proscia Inc., Agenus Inc., Lunit, BostonGene Corporation, PathAI, Inc., and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Digital Biomarkers market will grow by 2032? Click to get a snapshot of the Digital Biomarkers Market Analysis
https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=promotion&utm_campaign=gpr

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.